IDEAS home Printed from https://ideas.repec.org/r/eee/jhecon/v13y1994i4p383-406.html
   My bibliography  Save this item

Returns to R&D on new drug introductions in the 1980s

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. D. Sornette, 2002. "Economies of scale in innovations with block-busters," Quantitative Finance, Taylor & Francis Journals, vol. 2(3), pages 224-227.
  2. Hans H. Bauer & Marc Fischer & Volker Pfahlert, 2001. "Lohnt sich für Pharmaunternehmen der Markteintritt als Late Mover? — Ergebnisse einer Rentabilitätsanalyse," Schmalenbach Journal of Business Research, Springer, vol. 53(6), pages 632-648, September.
  3. Eric Helland & Seth A. Seabury, 2016. "Are Settlements in Patent Litigation Collusive? Evidence from Paragraph IV Challenges," NBER Working Papers 22194, National Bureau of Economic Research, Inc.
  4. Feller, Irwin & Nelson, Jon P., 1999. "The microeconomics of manufacturing modernization programs," Research Policy, Elsevier, vol. 28(8), pages 807-818, November.
  5. Martin E. Backhouse, 1998. "An investment appraisal approach to clinical trial design," Health Economics, John Wiley & Sons, Ltd., vol. 7(7), pages 605-619, November.
  6. Costello, Christopher & Ward, Michael, 2006. "Search, bioprospecting and biodiversity conservation," Journal of Environmental Economics and Management, Elsevier, vol. 52(3), pages 615-626, November.
  7. Toole, Andrew A., 2012. "The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry," Research Policy, Elsevier, vol. 41(1), pages 1-12.
  8. Bruce Rasmussen, 2010. "Innovation and Commercialisation in the Biopharmaceutical Industry," Books, Edward Elgar Publishing, number 13680.
  9. Austin, David, 2000. "Patents, Spillovers and Competition in Biotechnology," RFF Working Paper Series dp-00-53, Resources for the Future.
  10. George W. Blazenko & Andrey D. Pavlov, 2010. "Investment Timing for New Business Ventures," Journal of Entrepreneurial Finance, Pepperdine University, Graziadio School of Business and Management, vol. 14(3), pages 37-68, Fall.
  11. Scherer, F.M., 2010. "Pharmaceutical Innovation," Handbook of the Economics of Innovation, in: Bronwyn H. Hall & Nathan Rosenberg (ed.), Handbook of the Economics of Innovation, edition 1, volume 1, chapter 0, pages 539-574, Elsevier.
  12. Dahm, Matthias & González, Paula & Porteiro, Nicolás, 2018. "The enforcement of mandatory disclosure rules," Journal of Public Economics, Elsevier, vol. 167(C), pages 21-32.
  13. Ming Ding & Jehoshua Eliashberg, 2002. "Structuring the New Product Development Pipeline," Management Science, INFORMS, vol. 48(3), pages 343-363, March.
  14. Gleason, Katherine I. & Klock, Mark, 2006. "Intangible capital in the pharmaceutical and chemical industry," The Quarterly Review of Economics and Finance, Elsevier, vol. 46(2), pages 300-314, May.
  15. Joseph Dimasi & Henry Grabowski & John Vernon, 1995. "R&D Costs, Innovative Output and Firm Size in the Pharmaceutical Industry," International Journal of the Economics of Business, Taylor & Francis Journals, vol. 2(2), pages 201-219.
  16. Pascale Crama & Bert De Reyck & Zeger Degraeve & Wang Chong, 2007. "Research and Development Project Valuation and Licensing Negotiations at Phytopharm plc," Interfaces, INFORMS, vol. 37(5), pages 472-487, October.
  17. Scherer, F. M. & Harhoff, Dietmar, 2000. "Technology policy for a world of skew-distributed outcomes," Research Policy, Elsevier, vol. 29(4-5), pages 559-566, April.
  18. Toole, Andrew A., 2011. "The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry," ZEW Discussion Papers 11-063, ZEW - Leibniz Centre for European Economic Research.
  19. Casper, Steven & Matraves, Catherine, 2003. "Institutional frameworks and innovation in the German and UK pharmaceutical industry," Research Policy, Elsevier, vol. 32(10), pages 1865-1879, December.
  20. Anna Giunta & Filippo M. Pericoli & Eleonora Pierucci, 2016. "University–Industry collaboration in the biopharmaceuticals: the Italian case," The Journal of Technology Transfer, Springer, vol. 41(4), pages 818-840, August.
  21. Daniel R. Wilmoth, 2015. "Reconciling Estimates of the Value to Firms of Reduced Regulatory Delay in the Marketing of Their New Drugs," Health Economics, John Wiley & Sons, Ltd., vol. 24(12), pages 1651-1656, December.
  22. Jeffrey S. Stonebraker, 2002. "How Bayer Makes Decisions to Develop New Drugs," Interfaces, INFORMS, vol. 32(6), pages 77-90, December.
  23. Didier Sornette, 2007. "Nurturing Breakthroughs: Lessons from Complexity Theory," Papers 0706.1839, arXiv.org.
  24. Yaroslav Kryukov, "undated". "Dynamic R&D and the Effectiveness of Policy Intervention in the Pharmaceutical Industry," GSIA Working Papers 2015-E33, Carnegie Mellon University, Tepper School of Business.
  25. Dahm, Matthias & González, Paula & Porteiro, Nicolás, 2009. "Trials, tricks and transparency: How disclosure rules affect clinical knowledge," Journal of Health Economics, Elsevier, vol. 28(6), pages 1141-1153, December.
  26. DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2003. "The price of innovation: new estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 151-185, March.
  27. Park, Donghyun, 1998. "A proposal for measuring the benefits of policy-oriented social science research," Impact assessments 3, International Food Policy Research Institute (IFPRI).
  28. George G. Djolov, 2004. "Market Power And The Pharmaceutical Industry In South Africa," Economic Affairs, Wiley Blackwell, vol. 24(2), pages 47-51, June.
  29. Philipp N. Baecker, 2007. "Real Options and Intellectual Property," Lecture Notes in Economics and Mathematical Systems, Springer, number 978-3-540-48264-2, October.
  30. Morgan, Steve & Grootendorst, Paul & Lexchin, Joel & Cunningham, Colleen & Greyson, Devon, 2011. "The cost of drug development: A systematic review," Health Policy, Elsevier, vol. 100(1), pages 4-17, April.
  31. Neeraj Sood & Karen Mulligan & Kimberly Zhong, 2021. "Do companies in the pharmaceutical supply chain earn excess returns?," International Journal of Health Economics and Management, Springer, vol. 21(1), pages 99-114, March.
  32. Archibugi, Daniele & Bizzarri, Kim, 2004. "Committing to vaccine R&D: a global science policy priority," Research Policy, Elsevier, vol. 33(10), pages 1657-1671, December.
  33. Anna Long & Matthew S. Wood & Daniel L. Bennett, 2023. "Entrepreneurial organizing activities and nascent venture performance," Small Business Economics, Springer, vol. 60(2), pages 433-461, February.
  34. Hamdouch, A. & Depret, M.-H., 2000. "Coalitions industrielles, reseaux de firmes et dynamiques de concurrence-cooperation dans les secteurs en cours de globalisation : le cas de l'industrie pharmaceutique," Papiers d'Economie Mathématique et Applications 2000.24, Université Panthéon-Sorbonne (Paris 1).
  35. Giaccotto, Carmelo & Santerre, Rexford E & Vernon, John A, 2005. "Drug Prices and Research and Development Investment Behavior in the Pharmaceutical Industry," Journal of Law and Economics, University of Chicago Press, vol. 48(1), pages 195-214, April.
  36. Joseph P. Cook & Joseph Golec, 2017. "How excluding some benefits from value assessment of new drugs impacts innovation," Health Economics, John Wiley & Sons, Ltd., vol. 26(12), pages 1813-1825, December.
  37. Bauer, Hans H. & Fischer, Marc, 2000. "Product life cycle patterns for pharmaceuticals and their impact on R&D profitability of late mover products," International Business Review, Elsevier, vol. 9(6), pages 703-725, December.
  38. Lynne G. Zucker & Michael R. Darby, 1995. "Present at the Revolution: Transformation of Technical Identity for a Large Incumbent Pharmaceutical Firm After the Biotechnological Breakthrough," NBER Working Papers 5243, National Bureau of Economic Research, Inc.
  39. Gregor Dorfleitner & Felix Rößle, 2018. "The financial performance of the health care industry: a global, regional and industry specific empirical investigation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(4), pages 585-594, May.
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.